Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy

Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy

Abstract Melittin, the principal constituent in bee venom, is an attractive candidate for cancer therapy. However, its clinical applications are limited by hemolysis, nonspecific cytotoxicity, and rapid metabolism. Herein, a novel genetically engineered vesicular antibody‐melittin (VAM) drug deliver...

Full description

Bibliographic Details
Main Authors: Jianzhong Zhang, Xue Liu, Yutian Xia, Shuyu Xu, Xuan Liu, Haiqing Xiao, Xiaoyong Wang, Chao Liu, Gang Liu
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Bioengineering & Translational Medicine
Subjects:
Cancer therapy
Drug delivery
Melittin
Membrane vesicles
Nanomedicine
Online Access:https://doi.org/10.1002/btm2.10482

Internet

https://doi.org/10.1002/btm2.10482

Similar Items